



# An International Congress on Lymphoma, Myeloma, and Leukemia Disorders



## Lymphoma & Myeloma

October 17–20, 2018


New York City

**NEW DAY!**  
New Approaches  
in Acute Leukemias  
and Hematologic  
Malignancies

**Wednesday,  
October 17**

[lymphomaandmyeloma.com](http://lymphomaandmyeloma.com)

AN **IMEDEX** EVENT  
AN HMP COMPANY



# Lymphoma & Myeloma

## An International Congress on Hematologic Malignancies

For the past 18 years, the Lymphoma & Myeloma Congress has been recognized around the world as the most respected forum for industry-leading hematologic research—it's where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This year, make plans to join us for four days of comprehensive learning as we examine new research, discover innovative treatment methods, and analyze new trends impacting the future of lymphoma, myeloma, and leukemia disorders.



**CONGRESS CHAIR**  
**Morton Coleman, MD**  
Weill Cornell Medicine  
New York, New York



**CO-CHAIR,  
MYELOMA SESSION**  
**Ruben Niesvizky, MD**  
Weill Cornell Medicine  
New York, New York



**CO-CHAIR,  
ACUTE LEUKEMIA  
& HEMATOLOGIC  
MALIGNANCIES  
SESSION**

**Gail J. Roboz, MD**  
Weill Cornell Medicine  
New York, New York



**CO-CHAIR,  
LYMPHOMA SESSION**  
**John P. Leonard, MD**  
Weill Cornell Medicine  
New York, New York



**CO-CHAIR,  
CLL SESSION**  
**Richard R. Furman, MD**  
Weill Cornell Medicine  
New York, New York



## SUPPORT

The following companies are supporters of this Congress:

### GOLD

**Karyopharm  
Therapeutics**

**Seattle Genetics**

Several options are available for companies interested in supporting this Congress. For more information, please contact Imedex by email at [cme@imedex.com](mailto:cme@imedex.com).

## ENDORSED BY



“Lymphoma & Myeloma is genuinely one of the best meetings of the year. The detailed agenda allows for a deep dive into these complex diseases and provides practical advice for the treating clinician. The time allowed for Q&A makes this program unique, facilitating excellent interaction with the faculty, who are truly the leaders in the field. A mix of debates and didactic lectures keeps the audience engaged and encourages outstanding education.”



**Joseph Mikhael, MD**

Chief Medical Officer  
International Myeloma Foundation

*This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.*

# SCIENTIFIC AGENDA

## **NEW APPROACHES IN ACUTE LEUKEMIA & HEMATOLOGIC MALIGNANCIES WEDNESDAY, OCTOBER 17, 2018**

10:30 AM Welcome: *Gail J. Roboz, MD*

### **Session I: Acute Leukemias**

10:40 AM Pre-Session Audience Survey  
10:50 AM Diagnosis and Treatment of Newly Diagnosed ALL  
11:10 AM Immunotherapy of ALL  
11:30 AM DEBATE: Which Patients Should Be Transplanted for ALL?  
12:00 PM Panel Discussion and Post-Session Audience Survey  
12:15 PM Luncheon Programs

### **Session II: MPN & MDS**

1:45 PM Pre-Session Audience Survey  
1:55 PM Monitoring Patients on Longstanding TKI Therapy for CML:  
What to Look for Other Than BCR-ABL  
2:15 PM Treatment Strategies for Myelofibrosis  
2:35 PM MDS: Is Your Hypomethylator Working?  
2:55 PM DEBATE: Which Patients with CML Should Stop TKI Therapy?  
3:25 PM Panel Discussion and Post-Debate Audience Survey  
3:40 PM Break

### **Session III: Special Topics**

4:00 PM Pre-Session Audience Survey  
4:10 PM Newly Diagnosed AML: Hitting the Right Target  
4:30 PM AML: What to Do with Your 500-Gene Mutation Report  
4:50 PM MRD in AML: What is It and What Do I Do About It?  
5:10 PM AML 60-80 Years: Who Should Get an Allo Transplant?  
5:30 PM Panel Discussion and Post-Session Audience Survey  
5:45 PM Session Adjourn  
5:45 PM Exhibit Hall/Product Theater Opening







## MYELOMA SESSION

### THURSDAY, OCTOBER 18, 2018

8:00 AM Welcome: *Morton Coleman, MD*

8:05 AM Introduction to Myeloma  
Session: *Ruben Niesvizky, MD*

#### Session I: Precision Medicine in Myeloma

|         |                                                                                          |         |                                                                                         |
|---------|------------------------------------------------------------------------------------------|---------|-----------------------------------------------------------------------------------------|
| 8:10 AM | Pre-Session Audience Survey                                                              | 9:00 AM | DEBATE: MRD: Ready for Prime Time?                                                      |
| 8:20 AM | Genomics 101: From Deep Sequencing to Liquid Biopsies                                    |         | Yes, Is MRD for Novel Agents the Same as for Transplantation?                           |
| 8:40 AM | Genomics 102: Clinical Use for Treatment Individualization, Including Double-Hit Myeloma |         | No, MRD Does Inform Length of Induction, Need for Transplant/Consolidation, Maintenance |
|         |                                                                                          | 9:30 AM | Panel Discussion and Post-Session Audience Survey                                       |
|         |                                                                                          | 9:50 AM | Break                                                                                   |

#### Session II: Immuno-Oncology

|          |                                                                                               |          |                                                                 |
|----------|-----------------------------------------------------------------------------------------------|----------|-----------------------------------------------------------------|
| 10:10 AM | Pre-Session Audience Survey                                                                   | 11:20 AM | DEBATE: Is Allotransplant Relevant Today in Myeloma? Yes vs. No |
| 10:20 AM | Vaccination as a Therapeutic Approach in Myeloma                                              |          |                                                                 |
| 10:40 AM | Anti CD38, SLAMF-7, and BiTE Immunotherapy: Are Immune Therapeutics Ready for the Front Line? | 11:50 AM | Panel Discussion and Post-Debate Audience Survey                |
|          |                                                                                               | 12:10 PM | Lunch                                                           |
| 11:00 AM | CAR-T: State of the Art and Perspective of a Possible Cure                                    |          |                                                                 |

#### Session III: Treatment

|         |                                                                             |         |                                                   |
|---------|-----------------------------------------------------------------------------|---------|---------------------------------------------------|
| 1:40 PM | Pre-Session Audience Survey                                                 | 2:30 PM | Management of the Unfit and Frail Patient         |
| 1:50 PM | Precursor Disorders in Myeloma: Can We Cure Some?                           | 2:50 PM | Panel Discussion and Post-Session Audience Survey |
| 2:10 PM | Management of the Fit Patient: Induction, Which One to Choose, 3 or 4 Drugs | 3:10 PM | Break                                             |

#### Session IV: Special Lectures

|         |                                                                                            |         |                                      |
|---------|--------------------------------------------------------------------------------------------|---------|--------------------------------------|
| 3:30 PM | Best Myeloma Abstract Presentation                                                         | 4:10 PM | Keynote Lecture: Is Myeloma Curable? |
| 3:40 PM | New Horizons in the Treatment of Relapsed and Refractory Myeloma                           | 4:40 PM | Panel Discussion                     |
|         |                                                                                            | 4:50 PM | Adjourn                              |
| 4:00 PM | The SAAS Foundation for Medical Research Award: Michaeli Award for Contribution to Myeloma |         |                                      |



## CLL SESSION

FRIDAY, OCTOBER 19, 2018

8:00 AM Welcome: *Morton Coleman, MD*

8:05 AM Introduction to CLL Session:  
*Richard Furman, MD*

### Session V: Small Molecule Inhibitors

8:10 AM Pre-Session Audience Survey

9:00 AM Update on Venetoclax:  
How Low Can You Go (MRD)?

8:20 AM Update on BTK Inhibitors:  
Ibrutinib Plus the New Kids on  
the Block: Are They Better?

9:20 AM Panel Discussion and Post-  
Session Audience Survey

8:40 AM Update on PI3K Inhibitors:  
Idelalisib, Copanlisib, Duvelisib,  
Umbralisib: Is Toxicity the Key?

9:40 AM Break

### Session VI: The Future of CLL

10:00 AM Pre-Session Audience Survey

10:50 AM Does Sequence Matter  
for Novel Therapies?

10:10 AM Update on Chemotherapy in  
2018: Is Chemotherapy Passé?

11:10 AM What's Next in CLL?

10:30 AM Treatment Options for the  
Young Patient with Deletion 17p:  
Do They Need a Different  
Approach?

11:30 AM Panel Discussion and Post-  
Session Audience Survey

11:50 AM Session Adjourn

11:50 AM Luncheon Programs

### Session VII: Special Topics in CLL

1:20 PM Pre-Session Audience Survey

2:30 PM Bruce Waterfall Memorial  
Lecture: What are the Newest  
Therapies for Relapsed  
Refractory Waldenström  
Macroglobulinemia?

1:30 PM Ethnic, Environmental, Genetic,  
and Familial Risk Factors for CLL

2:50 PM Post-Session Audience Survey

1:50 PM Prince Family Lecture: Small  
RNAs and Their Role in CLL:  
Molecular Breakthroughs?

3:00 PM Break

2:10 PM Bruce Waterfall Memorial  
Lecture: What are the  
Best Front-Line Therapies  
for Waldenström  
Macroglobulinemia?

### Session VIII: CLL Transformation

3:20 PM Pre-Session Audience Survey


4:10 PM Where are We with CAR  
T-Cells in CLL? What are  
the Data? Does It Work for  
Transformation?

3:30 PM Gebroe Family Lecture: Can We  
Predict Who Will Get Richter's  
Transformation?

4:30 PM Panel Discussion and Post-  
Session Audience Survey

3:50 PM Therapeutic Options for  
Richter's Syndrome

4:50 PM Adjourn



## LYMPHOMA SESSION

### SATURDAY, OCTOBER 20, 2018

8:00 AM Welcome: *Morton Coleman, MD*

8:05 AM Introduction to Lymphoma  
Session: *John Leonard, MD*

#### Session IX: Special Topics in Lymphoma

|         |                                                                                  |         |                                                                            |
|---------|----------------------------------------------------------------------------------|---------|----------------------------------------------------------------------------|
| 8:10 AM | Pre-Session Audience Survey                                                      | 9:00 AM | Vitamin D in Lymphoma Therapy: What is Its Role, and Should We Supplement? |
| 8:20 AM | Patient-Derived Xenografts (PDX) in Lymphoma: How Can They Help Advance Therapy? | 9:20 AM | Panel Discussion and Post-Session Audience Survey                          |
| 8:40 AM | New Targets and Tools in Lymphoma Treatment                                      | 9:40 AM | Break                                                                      |

#### Session X: New Directions in Lymphoma

|          |                                                                                                   |          |                                                                                            |
|----------|---------------------------------------------------------------------------------------------------|----------|--------------------------------------------------------------------------------------------|
| 10:00 AM | Pre-Session Survey                                                                                | 10:40 AM | DEBATE: Is Obinutuzumab Superior to Rituximab in Lymphoma? Yes vs. No                      |
| 10:10 AM | DEBATE: What is the Best Upfront Approach for the Treatment of Advanced Stage Hodgkin's Lymphoma? | 11:10 AM | Auto-Transplant vs. CAR-T: How Should We Sequence Therapy, and Who Should Receive Therapy? |
|          | Side 1: A (Brentuximab Vedotin) VD                                                                | 11:30 AM | Panel Discussion and Post-Session Audience Survey                                          |
|          | Side 2: A (Bleomycin) VD                                                                          |          |                                                                                            |

#### Session XI: Immunotherapy in Lymphoma

|          |                                                         |          |                   |
|----------|---------------------------------------------------------|----------|-------------------|
| 11:50 AM | Presentation of Best Lymphoma Abstract                  | 12:40 PM | Discussion        |
| 12:00 PM | The SAAS Foundation for Medical Research Award Ceremony | 12:45 PM | Session Adjourn   |
| 12:10 PM | Immunotherapy of Hodgkin's and Non-Hodgkin's Lymphoma   | 12:45 PM | Luncheon Programs |

#### Session XII-A: Breakouts: Indolent and Mantle Cell Lymphoma

|         |                                                                                 |         |                                                                   |
|---------|---------------------------------------------------------------------------------|---------|-------------------------------------------------------------------|
| 2:15 PM | Breakout #1: New Data on Upfront and Maintenance Therapy in Follicular Lymphoma | 3:15 PM | Breakout #4: Novel Agents and Approaches for Mantle Cell Lymphoma |
| 2:35 PM | Breakout #2: How I Approach Early Relapsing Follicular Lymphoma                 | 3:35 PM | Break                                                             |
| 2:55 PM | Breakout #3: How I Approach the Initial Treatment of Mantle Cell Lymphoma       |         |                                                                   |



## LYMPHOMA SESSION

**SATURDAY, OCTOBER 20, 2018**

### Session XII-B: Breakouts: Aggressive and T-Cell Lymphoma (Concurrent with XII-A)

|         |                                                                         |         |                                                                                               |
|---------|-------------------------------------------------------------------------|---------|-----------------------------------------------------------------------------------------------|
| 2:15 PM | Breakout #5: How Should We Treat Double-Hit and Double-Expressor DLBCL? | 2:55 PM | Breakout #7: New Developments in Primary and Secondary CNS Lymphoma: Prevention and Treatment |
| 2:35 PM | Breakout #6: New Drugs for Aggressive Lymphoma                          | 3:15 PM | Breakout #8: Novel Approaches for T-Cell Lymphoma                                             |
|         |                                                                         | 3:35 PM | Break                                                                                         |

### Session XIII-A: Breakouts: Indolent and Mantle Cell Lymphoma


|         |                                                                                 |         |                                                                           |
|---------|---------------------------------------------------------------------------------|---------|---------------------------------------------------------------------------|
| 3:55 PM | Breakout #1: New Data on Upfront and Maintenance Therapy in Follicular Lymphoma | 4:35 PM | Breakout #3: How I Approach the Initial Treatment of Mantle Cell Lymphoma |
| 4:15 PM | Breakout #2: How I Approach Early Relapsing Follicular Lymphoma                 | 4:55 PM | Breakout #4: Novel Agents and Approaches for Mantle Cell Lymphoma         |
|         |                                                                                 | 5:15 PM | Adjourn                                                                   |

### Session XIII-B: Breakouts: Aggressive and T-Cell Lymphoma

|         |                                                                         |         |                                                                                               |
|---------|-------------------------------------------------------------------------|---------|-----------------------------------------------------------------------------------------------|
| 3:55 PM | Breakout #5: How Should We Treat Double-Hit and Double-Expressor DLBCL? | 4:35 PM | Breakout #7: New Developments in Primary and Secondary CNS Lymphoma: Prevention and Treatment |
| 4:15 PM | Breakout #6: New Drugs for Aggressive Lymphoma                          | 4:55 PM | Breakout #8: Novel Approaches for T-Cell Lymphoma                                             |
|         |                                                                         | 5:15 PM | Adjourn                                                                                       |







## CONCURRENT NURSE PRACTITIONER AND PHYSICIAN ASSISTANT SESSIONS THURSDAY, OCTOBER 18, 2018

### Session I: Updates in Multiple Myeloma

|          |                                                                 |          |                                                                          |
|----------|-----------------------------------------------------------------|----------|--------------------------------------------------------------------------|
| 8:45 AM  | Welcome and Introduction of<br>Track: <i>Morton Coleman, MD</i> | 10:25 AM | Role of Transplant in Multiple<br>Myeloma                                |
| 8:55 AM  | Track Overview:<br><i>Jeremy T. Heinerich, PA-C</i>             | 11:25 AM | Interpretation of Bone Marrow<br>Biopsies in Hematologic<br>Malignancies |
| 9:00 AM  | Pre-Session Audience Survey                                     | 12:25 PM | Post-Session Audience Survey                                             |
| 9:10 AM  | Role of Immunomodulating<br>Agents in Multiple Myeloma          | 12:35 PM | Lunch                                                                    |
| 10:10 AM | Break                                                           |          |                                                                          |

## FRIDAY, OCTOBER 19, 2018

### Session II: Updates in CLL

|         |                                                                 |          |                                                 |
|---------|-----------------------------------------------------------------|----------|-------------------------------------------------|
| 8:45 AM | Welcome and Introduction of<br>Track: <i>Morton Coleman, MD</i> | 9:15 AM  | Managing Toxicities of Oral<br>Therapies in CLL |
| 8:55 AM | Track Overview:<br><i>Jeremy T. Heinerich, PA-C</i>             | 10:15 AM | Break                                           |
| 9:05 AM | Pre-Session Audience Survey                                     | 10:35 AM | Role of MRD Negativity in CLL                   |
|         |                                                                 | 11:35 AM | Post-Session Audience Survey                    |
|         |                                                                 | 11:45 AM | Lunch                                           |

## SATURDAY, OCTOBER 20, 2018

### Session III: Hands-On Workshops in Lymphoma

|          |                                                                 |          |                            |
|----------|-----------------------------------------------------------------|----------|----------------------------|
| 8:20 AM  | Welcome and Introduction of<br>Track: <i>Morton Coleman, MD</i> | 11:00 AM | CAR T-Cell in Lymphoma     |
| 8:25 AM  | Track Overview:<br><i>Jeremy T. Heinerich, PA-C</i>             | 12:00 PM | Hodgkin's Lymphoma Updates |
| 8:30 AM  | Bone Marrow Biopsy Workshop                                     | 1:00 PM  | Lunch                      |
| 9:30 AM  | Lumbar Puncture Workshop                                        |          |                            |
| 10:30 AM | Break                                                           |          |                            |



*"The concentration of clinical treatment, prognostic, and biologic advances in lymphoma, myeloma, and CLL, as well as how they impact current practice care, is the key strength and takeaway."*



## CONTINUING EDUCATION

### Physicians



Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved for *AMA PRA Category 1 Credits™*.

### Maintenance of Certification



ABIM MOC Successful completion of this CME activity enables a participant to earn MOC points towards the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

### Pharmacy



Imedex®, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

### Nursing



In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### Who Should Attend

This educational activity is designed for domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies.

### Learning Objectives

Upon successful completion of these educational activities, participants should be better able to:

- » Interpret efficacy and safety results from recent clinical trials that led to the approval of new pharmacologic agents for the treatment of leukemias, lymphomas, or myeloma
- » Assess the prognostic impact of molecular biomarkers and genetic mutations that are common to hematologic malignancies
- » Evaluate the emerging role of immunotherapies as an intervention for hematologic malignancies that are known to have an immunologic component
- » Devise tailored therapeutic strategies designed to realize optimal therapeutic response from hematologic cancer patients who are either fit or frail
- » Describe the mechanisms of action of new or emerging treatments that are designed to target molecular biomarkers or genetic aberrations that are frequently observed in hematologic cancers
- » Assess both established and recently pioneered sequencing and combination strategies for second-line or salvage therapy interventions

## EXHIBITORS

Exhibit space is available for companies interested in exhibiting at this Congress. For more information, please contact Imedex at 678.242.0719 or [exhibits@imedex.com](mailto:exhibits@imedex.com).



# Congress Location and Accommodations

## Sheraton New York Times Square Hotel

811 W. 7th Avenue  
New York, New York 10019

Special Room Rate:  
\$324/night plus tax





Reserve Your Room Online at: [aws.passkey.com/go/lmedex2018](https://aws.passkey.com/go/lmedex2018)

| REGISTRATION<br>RATES                                     | EARLY<br>Through<br>7/31/18 | DISCOUNTED<br>8/1/18 –<br>9/14/18 | REGULAR/<br>ONSITE<br>9/15/18 –<br>10/20/18 |
|-----------------------------------------------------------|-----------------------------|-----------------------------------|---------------------------------------------|
| Physician, Pharmacist,<br>and Non-Clinician<br>Researcher | \$549                       | \$349                             | \$749                                       |
| Physician Assistant,<br>Nurse Practitioner                | \$349                       | \$399                             | \$449                                       |
| Nurse, Fellow,<br>Resident, Student,<br>Trainee           | \$199                       | \$249                             | \$299                                       |
| Pharmaceutical<br>Personnel                               | \$899                       |                                   |                                             |

Register by July 31, 2018  
to secure your place at the  
best rate.

Register online at  
[lymphomaandmyeloma.com](https://lymphomaandmyeloma.com)  
or call  
800.233.0957 (US)  
1.678.242.0906 (INTL)



**Lymphoma  
& Myeloma**

**IMEDEX**  
AN HMP COMPANY  
11675 Rainwater Drive, Suite 600  
Alpharetta, GA 30009, USA

**An International  
Congress on Hematologic  
Malignancies**

**October 17–20, 2018 | New York, NY**

**Register by July 31 to reserve  
your seat at the best rate.**

**[lymphomaandmyeloma.com](http://lymphomaandmyeloma.com)**